BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36124593)

  • 21. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
    Zhang G; Luo Y; Dong W; Zhong W
    Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value and potential mechanism of Matrix Metalloproteinases among Prostate Cancer.
    Geng X; Chen C; Huang Y; Hou J
    Int J Med Sci; 2020; 17(11):1550-1560. PubMed ID: 32669958
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy.
    Luan J; Zhang Q; Song L; Wang Y; Ji C; Cong R; Zheng Q; Xu Z; Xia J; Song N
    Transl Androl Urol; 2021 Mar; 10(3):1018-1029. PubMed ID: 33850736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
    Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
    Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 27. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
    Shao N; Tang H; Mi Y; Zhu Y; Wan F; Ye D
    Oncoimmunology; 2020 Jun; 9(1):1762473. PubMed ID: 32923125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
    Yan Z; Gao Y; Yu J; Shen Z; Bu X
    J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
    Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
    Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
    Chen L; Zhang M; Zhou J; Zhang L; Liang C
    Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
    Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
    Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
    [No Abstract]   [Full Text] [Related]  

  • 34. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
    Tian M; Yang J; Han J; He J; Liao W
    Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma.
    Song D; Tian J; Han X; Li X
    Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3467-3477. PubMed ID: 33449165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
    Xu HH; Wang HL; Xing TJ; Wang XQ
    Front Immunol; 2022; 13():851622. PubMed ID: 35924232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma.
    Xiao Z; Li J; Yu Q; Zhou T; Duan J; Yang Z; Liu C; Xu F
    Front Pharmacol; 2021; 12():778294. PubMed ID: 35002712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.